Superluminal Medicines, Eli Lilly forge USD 1.3 billion alliance to advance Small Molecule Therapeutics
Boston: Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology to rapidly unlock the most challenging G protein-coupled receptors (GPCRs), has announced a collaboration with Eli Lilly and Company to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and obesity.
The collaboration will leverage Superluminal's cutting-edge, structure-based drug discovery platform, combined with Lilly's small molecule development and commercialization expertise, to rapidly advance potentially life-changing therapeutics.
"Our collaboration with Lilly is a defining moment for Superluminal, and a testament to the power of our platform to deliver high-quality development candidates against historically intractable GPCR targets," said Cony D'Cruz, CEO of Superluminal. "Together, we aim to develop next-generation medicines that address the urgent and growing global burden of cardiometabolic disease. We are very excited to be embarking on this collaboration just as we begin to advance our internal drug candidate targeting rare genetic forms of obesity and hypothalamic obesity, and we are committed to bringing safe, efficacious, novel treatments to patients affected by these challenging conditions."
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.